Recommendation of the President – Emcitate (tiratricol)

On 27 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 161/2024 on the appropriateness of granting reimbursement approval for Emcitate (tiratricol) for the indication: Allan-Herndon-Dudley syndrome

Publication in Public Information Bulletin (BIP) >>